Vlado Perkovic's Publications

Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis
Conference Papers
2022
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy
Conference Papers
2022
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D
Conference Papers
2022
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy
Journal articles
2022
Journal of the American Society of Nephrology
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy
Journal articles
2022
Journal of the American Society of Nephrology
A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)
Journal articles
2022
Journal of the American Society of Nephrology
On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D
Journal articles
2022
Journal of the American Society of Nephrology
Gene Polymorphism in Organic Anion Transporters Determine the Long-Term Efficacy and Safety of Atrasentan in Patients With Type 2 Diabetes and CKD
Journal articles
2022
Journal of the American Society of Nephrology
Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD
Journal articles
2022
Journal of the American Society of Nephrology
Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis
Journal articles
2022
Journal of the American Society of Nephrology
EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISONE IN IGA NEPHROPATHY: THE TESTING TRIAL
Conference Abstracts
2022
NEPHROLOGY
Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials
Journal articles
2022
Hypertension
POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS
Conference Posters
2022
POS-019 A NOVEL RISK PREDICTION MODEL FOR SERVE ACUTE KIDNEY INJURY IN INTENSIVE CARE UNIT PATIENTS RECEIVING FLUID RESUSCITATION
Conference Abstracts
2022
Kidney International Reports
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial
Journal articles
2021
European Heart Journal
Daprodustat for the treatment of anemia in patients not undergoing dialysis
Journal articles
2021
New England Journal of Medicine
Daprodustat for the treatment of anemia in patients undergoing dialysis
Journal articles
2021
New England Journal of Medicine
Association between circulating gdf-15 and cardio-renal outcomes and effect of canagliflozin: Results from the canvas trial
Journal articles
2021
Journal of the American Heart Association
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function A Post Hoc Analysis of the SONAR Randomized Trial
Journal articles
2021
Clinical Journal of the American Society of Nephrology
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics
Journal articles
2021
American Journal of Nephrology
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis
Journal articles
2021
Diabetes, Obesity and Metabolism
Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: A prespecified analysis from the SONAR trial
Journal articles
2021
Journal of the American Society of Nephrology
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbAinf1cinf, disease duration and treatment intensity: results from the CANVAS Program
Journal articles
2021
Diabetologia
Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial
Journal articles
2021
European Heart Journal
Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial
Conference Papers
2021
EUROPEAN HEART JOURNAL
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
Journal articles
2021
Diabetologia

Previous Next

Vlado Perkovic's Publications

Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis

Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy

On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D

Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy

A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)

On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D

Gene Polymorphism in Organic Anion Transporters Determine the Long-Term Efficacy and Safety of Atrasentan in Patients With Type 2 Diabetes and CKD

Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD

Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis

EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISONE IN IGA NEPHROPATHY: THE TESTING TRIAL

Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials

POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS

POS-019 A NOVEL RISK PREDICTION MODEL FOR SERVE ACUTE KIDNEY INJURY IN INTENSIVE CARE UNIT PATIENTS RECEIVING FLUID RESUSCITATION

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial

Daprodustat for the treatment of anemia in patients not undergoing dialysis

Daprodustat for the treatment of anemia in patients undergoing dialysis

Association between circulating gdf-15 and cardio-renal outcomes and effect of canagliflozin: Results from the canvas trial

The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function A Post Hoc Analysis of the SONAR Randomized Trial

The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics

Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: A prespecified analysis from the SONAR trial

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbAinf1cinf, disease duration and treatment intensity: results from the CANVAS Program

Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country